Skye Bioscience: Promising Nimacimab Data Supports Buy Rating

Skye Bioscience, Inc. (NASDAQ: SKYE ) stock is having a good month with double-digit gains and even firmer (+145%) over the past 6 months. The current gains could be cemented by the most recent positiveGamu Dave Innocent Pasi is a seasoned financial professional and writer, bringing a wealth of experience from his prior roles as a financial analyst and in investment research. With a strong background in analyzing financial statements, capital markets, and the macro-economy, Gamu has a proven track record of ...